cdbio.cnCrawled Nov 7, 2026
The page features the company’s product portfolio, including vaccines.
The company shares news and updates about its vaccines and global initiatives.
辽宁成大生物股份有限公司 discloses corporate information and operational details.
The company provides academic and public education on its vaccines and global market reach.
辽宁成大生物股份有限公司 outlines its history, vaccine products, and global distribution.
辽宁成大生物股份有限公司 develops and produces human rabies and Japanese encephalitis vaccines.
辽宁成大生物股份有限公司 highlights its vaccines, including 成大速达 rabies vaccine and 成大利宝 Japanese encephalitis vaccine.
Chengda Biotechnology acquires Viltech’s quadrivalent enterovirus vaccine technology for **RMB 46 million**, expanding its hand-foot-mouth disease (HFMD) vaccine pipeline beyond the EV71 strain. The deal covers rights to a **recombinant vaccine platform** using *Hansenula polymorpha*, which has received an **approval notice for clinical trials**. Chengda strengthens its position in pediatric infectious disease vaccines with this acquisition.
Oct 2026Insight, China's Pharmaceutical IndustryNews article
Liaoning ChengDa Biotechnology and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS) collaborate to create the **Beijing Key Laboratory for Synthetic Immunology and Vaccine Intelligent Manufacturing**. The lab aims to accelerate vaccine development for emerging and sudden infectious diseases, particularly arthropod-borne pathogens, by connecting advanced research with industrial applications. The partnership targets faster responses to infectious disease outbreaks through synthetic immunology techniques.
Nov 2025Insight, China's Pharmaceutical IndustryNews article
Liaoning Chengda Biotechnology Co., Ltd. (SHA: 688739) proposes a shift in its controlling shareholder’s actual controller. The State-owned Assets Supervision and Administration Commission of Liaoning Provincial Government will no longer oversee the controlling stakeholder, Liaoning Chengda Co., Ltd. This move removes state ownership influence from the company’s governance structure.
Feb 2025Insight, China's Pharmaceutical IndustryNews article
Liaoning Chengda Biotechnology secures NMPA approval for its ACYW135 meningococcal vaccine, targeting meningitis caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The polysaccharide conjugate vaccine addresses epidemic cerebrospinal meningitis, expanding China’s domestic vaccine pipeline. The company, listed on the Shanghai Stock Exchange (SHA: 688739), now advances toward potential commercialization.
Nov 2022Insight, China's Pharmaceutical IndustryNews article
